Switzerland· 66130008

Intuniv

A guanfacine product containing guanfacinum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC C02AC02

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedIntunivATCC02AC02REGISTER NO.66130008PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Guanfacine is registered in 14 of 19 countries.

Countries holding a registration under ATC C02AC02 (guanfacine), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Guanfacine · ATC C02AC02

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of guanfacine costs, country by country.

Normalised to the WHO defined daily dose (3 mg), the median price runs from $0.21 in United States to $7.74 in Switzerland — a ×37 gap.

  • Switzerland: $7.74 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Guanfacine · price per daily dose (3 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$7.74
  • US United States$0.21 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
guanfacinum
Manufacturer
—
Country
Switzerland (CH)
ATC code
C02AC02
ATC class
Guanfacine
Defined daily dose
3 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680661300089
    28 Stk
    CHF 105.25

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

163 interactions on record for guanfacine.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Guanfacine · interactions on record

163 records

  • 30 severe
  • 133 moderate

Most severe, free to view

  • AprepitantA04AD12severe
  • DexamethasoneH02AB02severe
  • KetoconazoleH02CA03severe
  • ChloramphenicolJ01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Guanfacine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All guanfacine products

Authorised across Europe · EMA

The same active substance is authorised in 5 EEA countries. Names it is sold under:

  • Germany · Guanfacin Neuraxpharm
  • United Kingdom (Northern Ireland) · Guanfacine Crescent
  • Iceland · Intuniv, Paxneury
  • Liechtenstein · Intuniv, Paxneury
  • Norway · Intuniv, Paxneury

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bcbf436f-023c-4c84-8a12-42907733037d
GET /v1/drugs/bcbf436f-023c-4c84-8a12-42907733037d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "guanfacinum 4 mg",
  "valid_from": "2018-08-01",
  "limitations": "[{\"description\":\"Nur zur secondline Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Rahmen eines umfassenden Therapieprogramms, bei Kindern und Jugendlichen im Alter von 6 - 17 Jahren die die DSM-IV-Kriterien oder die ICD-10-Klassifikation für ADHS aufweisen, wenn eine Behandlung mit Stimulanzien nicht ausreichend wirksam oder auf Grund von unerwünschten Wirkungen oder Fehlgebrauchs nicht indiziert ist.<br>\\nDie Behandlung soll nur von Ärztinnen bzw. Ärzten, die auf Verhaltensstörungen von Kindern und Jugendlichen spezialisiert sind, begonnen werden und muss auch von ihnen überwacht werden.<br>\\nWenn Patienten über 1 Jahr hinaus behandelt werden, so hat eine erneute Überprüfung der Behandlungsnotwendigkeit durch einen Arzt zu erfolgen, der über das notwendige Fachwissen in der Behandlung der ADHS verfügt.<br>\\nVergütet wird 1 Kleinpackung pro Patient pro 7 Tage oder 1 Grosspackung pro 28 Tage. Die Takeda Pharma AG, 8152 Glattpark-Opfikon (Zürich), zahlt nach Aufforderung durch denjenigen Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, pro weitere Packung 100 Prozent des Fabrikabgabepreises der günstigeren Packung an den Krankenversicherer zurück. Die Mehrwertsteuer kann nicht zusätzlich zu den Rückvergütungsbeträgen zurückgefordert werden. Die Aufforderung zur Rückvergütung soll in der Regel innerhalb von 6 Monaten erfolgen.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"20663.01\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2018-08-01\",\"validTo\":null}]",
  "galenic_form": "Ret Tabl 4 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2018-08-01",
  "self_retention_pct": 10
}

See everything about guanfacine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.